Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196.SH): New Indication Application for Fuweisili Citrate Capsules Approved

Stock News

Sep 15

Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196.SH) announced that its controlling subsidiary Jinzhou Aohong Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for a new indication application for Fuweisili citrate capsules (trade name: Futoning, project code: FCN-437c).

The newly approved indication is for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, to be used in combination with aromatase inhibitors as initial endocrine therapy.

The drug is an innovative small molecule CDK4/6 inhibitor with proprietary intellectual property rights owned by the Group. It is an oral, potent, highly selective, novel-structure innovative small molecule drug that was included in the national "Major New Drug Development" major science and technology project in 2018.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1196672556"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1196672556\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1196672556?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-15 16:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196672556","market":"sg","top_or_hot":-1,"title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196.SH): New Indication Application for Fuweisili Citrate Capsules Approved","media":"Stock News","content":"<p>Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196.SH) announced that its controlling subsidiary Jinzhou Aohong Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for a new indication application for Fuweisili citrate capsules (trade name: Futoning, project code: FCN-437c).</p>\n<p>The newly approved indication is for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, to be used in combination with aromatase inhibitors as initial endocrine therapy.</p>\n<p>The drug is an innovative small molecule CDK4/6 inhibitor with proprietary intellectual property rights owned by the Group. It is an oral, potent, highly selective, novel-structure innovative small molecule drug that was included in the national \"Major New Drug Development\" major science and technology project in 2018.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196.SH): New Indication Application for Fuweisili Citrate Capsules Approved</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196.SH): New Indication Application for Fuweisili Citrate Capsules Approved\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-15 16:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196.SH) announced that its controlling subsidiary Jinzhou Aohong Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for a new indication application for Fuweisili citrate capsules (trade name: Futoning, project code: FCN-437c).</p>\n<p>The newly approved indication is for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, to be used in combination with aromatase inhibitors as initial endocrine therapy.</p>\n<p>The drug is an innovative small molecule CDK4/6 inhibitor with proprietary intellectual property rights owned by the Group. It is an oral, potent, highly selective, novel-structure innovative small molecule drug that was included in the national \"Major New Drug Development\" major science and technology project in 2018.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0196","symbol_name":"行业龙头","start_time":0,"source_url":"","article_id":"1196672556","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196672556","pubTimestamp":1757926220,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196.SH) announced that its controlling subsidiary Jinzhou Aohong Pharmaceutical Co., Ltd. has received approval from the National Medical Products...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0196":"行业龙头","BK0187":"一线龙头","BK0060":"抗癌","02196":"复星医药","BK0028":"国家队","BK0175":"白马股","BK0239":"医药制造","BK0183":"MSCI概念","BK0188":"融资融券","BK1515":"抗疫概念","BK1191":"制药","BK0096":"民营医院","BK1593":"医美概念股","BK0012":"证金概念"},"translate_title":"上海复星医药（集团）股份有限公司。（600196.SH）：枸橼酸福维思利胶囊新适应症申请获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196.SH) announced that its controlling subsidiary Jinzhou Aohong Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for a new indication application for Fuweisili citrate capsules (trade name: Futoning, project code: FCN-437c).\nThe newly approved indication is for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, to be used in combination with aromatase inhibitors as initial endocrine therapy.\nThe drug is an innovative small molecule CDK4/6 inhibitor with proprietary intellectual property rights owned by the Group. It is an oral, potent, highly selective, novel-structure innovative small molecule drug that was included in the national \"Major New Drug Development\" major science and technology project in 2018.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}